A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-05-19
Adverse events
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 2); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 5); relationship: Y
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 70); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 195); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 210); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 230); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 294); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-06-07 (study day 371); relationship: not assessed
Data queries
No data queries.